Obsidian Therapeutics (NASDAQ:OBX) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Obsidian Therapeutics (NASDAQ:OBX) from a hold rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

Several other equities analysts have also issued reports on the stock. William Blair raised shares of Obsidian Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Piper Sandler began coverage on shares of Obsidian Therapeutics in a research report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price objective for the company. Leerink Partners began coverage on Obsidian Therapeutics in a research note on Tuesday, September 22nd. They set an “outperform” rating and a $32.00 price objective on the stock. Lifesci Capital initiated coverage on Obsidian Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 target price on the stock. Finally, Weiss Ratings started coverage on Obsidian Therapeutics in a research note on Wednesday, September 2nd. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Obsidian Therapeutics Price Performance

Obsidian Therapeutics stock traded up $0.08 during midday trading on Friday, hitting $12.56. 314,041 shares of the stock were exchanged, compared to its average volume of 543,763. The firm has a fifty day moving average price of $14.28. Obsidian Therapeutics has a 52 week low of $9.60 and a 52 week high of $49.97.

Obsidian Therapeutics (NASDAQ:OBX) last issued its earnings results on Thursday, November 12th. The company reported ($1.23) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.80). As a group, analysts predict that Obsidian Therapeutics will post -1.81 EPS for the current fiscal year.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics is a biotechnology company developing engineered cell therapies for cancer. Its research focuses on modifying immune cells to improve their ability to target tumors and function within the body. The company’s programs include OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) therapy being developed for solid tumors. Obsidian’s cytoDRiVE platform is designed to regulate the activity of therapeutic proteins using small molecules, with the aim of controlling and optimizing cell therapies.